Chief of the Division of Neurosurgery
Children's Hospital of Philadelphia
I am chief of the Division of Neurosurgery at The Children’s Hospital of Philadelphia and an attending neurosurgeon specializing in pediatric brain tumors. I operate on every type of brain tumor, but I have a particular interest in low-grade gliomas, medulloblastomas and atypical teratoid rhabdoid tumors (AT/RT) as well as skull-base tumors such as acoustic neuromas, craniopharyngiomas, and large ependymomas in cerebellopontine angle. With my otolaryngologist colleagues I am also developing an endonasal skull base program at CHOP.
It is my privilege to partner with The Children’s Hospital of Philadelphia Research Institute, which is at the forefront of pediatric genetic research. Here we are working to develop new treatments that one day will help thousands of children with brain tumors. Currently, tissue from every brain tumor we treat is sent to the laboratory for sequencing to detect genetic abnormalities. Tumors that look identical under the microscope may in fact have significant genetic variations, explaining why one tumor may respond well to chemotherapy and radiation, and another may not. Our goal is to personalize the post-operative chemotherapy and radiation regimen by specifically targeting the treatment based on the genetic abnormality.
At CHOP we are also conducting research into the cell signaling mechanisms of brain tumors and are supported by several competitive grants including the NIH. Once we have identified an abnormality in the DNA code, the challenge is to then figure out how that abnormality translates into a functional abnormality. Once we understand that we have a new potential tumor target.
An example: we have recently found that the B-Raf gene is altered in many low- and high-grade gliomas in children. B-Raf is the same gene that is often abnormal in melanoma. Now we are collaborating with pharmaceutical companies who have already developed promising melanoma drugs and we have begun applying these medicines to our brain tumor specimens. If it turns out that a brain tumor with a B-Raf mutation behaves in the same way as melanoma, we could have an effective new treatment in the next few years.
There are countless reasons patients come to CHOP first for the best care. It is important for brain tumor patients to have their surgery at CHOP because we are currently unable to enroll tumors resected elsewhere into our genetic sequencing protocol. Without the genetic information not all the benefits of our groundbreaking research and experience would be available to the patient.
Ultimately, surgery is not the answer. We can take the tumor out but the biology of most of these tumors is such that they will come back. A cure for brain tumors lies in better understanding of their biology so we can develop more effective post-operative treatments to prevent them from recurring.
The collaborative spirit at CHOP is remarkable. Working with the basic science and tumor research teams, with access to the most advanced technology, we are now on an exciting precipice, poised for exponential growth in the near future. Hopefully in the next decade or two the new discoveries and therapies will put me out of the tumor business - which is really the ultimate goal.
Children’s Hospital of Philadelphia
Whole Genome Sequencing and RNA Sequencing of the CBTN Bank for the Pediatric Brain Tumor Atlas
Research into adult cancer has benefited greatly from large scale genomic research. Until now due to the limited resources and availability pediatric brain tumors have not been part of large-scale genomic generation efforts. The CBTN aims to create a comprehensive genomic atlas for use by researchers worldwide to unlock how brain tumors develop, grow, survive, and how they can be treated and cured.
Craniopharyngioma, Medulloblastoma, HGG, (AT/RT), LGG, Ependymoma, Ganglioglioma, DNET, Choroid Plexus Tumors, Meningioma, DIPG, Oligodendroglioma, Schwannoma, Germinoma, Choroid Plexus Tumors, Subependymal Giant cell Astrocytoma, NGGCTs
Indigenous peoples and inclusion in clinical and genomic research: Understanding the history and navigating contemporary engagement
The survival rates for pediatric cancer patients have improved significantly, but there are still significant disparities among underrepresented racial and ethnic groups. To address this issue, the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and Children's Brain Tumor Network (CBTN) created a
Angela Waanders, Alex Brown, Nadine R. Caron, Alexa Plisiewicz, Sean T. McHugh, Thinh Q. Nguyen, Kaitlin Lehmann, Jeffrey Stevens, Phillip J. Storm, Adam Resnick, Tom Belle Davidson, Sabine Mueller, Cassie Kline
Retrospective dataset and survey analyses identify gaps in data collection for craniopharyngioma and priorities of patients and families affected by the disease
Craniopharyngioma is a rare type of brain tumor located in the suprasellar region of the brain, close to important structures like the pituitary gland. This study aimed to better understand patient outcomes associated with existing therapies and to inform new treatment strategies. Our team collected
Emily Marshall, Nikhil Joshi, Julia Crowley, Shana McCormack, Sylvia Cheng, Walter Faig, Phillip B. Storm, Adam Resnick, Sabine Mueller, Fatema Malbari, Cassie Kline
Unsupervised machine learning using K-means identifies radiomic subgroups of pediatric low-grade gliomas that correlate with key molecular markers
This study aimed to investigate if an unsupervised machine learning approach based on radiomic features could reveal distinct imaging subtypes of pediatric low-grade gliomas (pLGGs). The researchers collected multi-parametric MR images from 157 patients with pLGGs and extracted quantitative radiom
Debanjan Haldar, Anahita Fathi Kazerooni, Sherjeel Arif, Ariana Familiar, Rachel Madhogarhia, Nastaran Khalili, Sina Bagheri, Hannah Anderson, Ibraheem Salman Shaikh, Aria Mahtabfar, Meen Chul Kim, Wenxin Tu, Jefferey Ware, Arastoo Vossough, Christos Davatzikos, Phillip B. Storm, Adam Resnick, Ali Nabavizadeh
Pediatric Blood & Cancer
BRAF Fusions in Pediatric Histiocytic Neoplasms Define Distinct Therapeutic Responsiveness to RAF Paradox Breakers
Pediatric histiocytic neoplasms are hematopoietic disorders frequently driven by the BRAF‐V600E mutation. Here, we identified two BRAF gene fusions (novel MTAP‐BRAF and MS4A6A‐BRAF) in two aggressive histiocytic neoplasms. In contrast to previously described BRAF fusions, MTAP‐BRAF and MS4A6A‐BRAF d
Payal Jain Lea F. Surrey Joshua Straka Pierre Russo Richard Womer Marilyn M. Li Phillip B. Storm Angela J. Waanders Michael D. Hogarty Adam C. Resnick Jennifer Picarsic
American Society of Clinical Oncology
NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome
Neurotrophic tyrosine receptor kinase (NTRK) fusions have been described as oncogenic drivers in a variety of tumors. However, little is known about the overall frequency of NTRK fusion in unselected pediatric tumors. Here, we assessed the frequency, fusion partners, and clinical course in pediatric
Xiaonan Zhao, PhD; Chelsea Kotch, MD; Elizabeth Fox, MD; Lea F. Surrey, MD; Gerald B. Wertheim, MD, PhD; Zubair W. Baloch, MD, PhD; Fumin Lin, PhD; Vinodh Pillai, MD, PhD; Minjie Luo, PhD; Portia A. Kreiger, MD; Jennifer E. Pogoriler, MD, PhD; Rebecca L. Linn, MD; Pierre A. Russo, MD; Mariarita Santi, MD, PhD; Adam C. Resnick, PhD; Phillip B. Storm, MD, PhD; Stephen P. Hunger, MD; Andrew J. Bauer, MD; and Marilyn M. Li, MD